Lung

Study Name: CYBRID-01

• Cancer Stage: I-III
• Key Inclusion: CT guided Bx
• Description: Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform (CYBRID-01)for Participants with Stage IV Lung Cancer.
• Study Number: ELEP-2022-CYBRID-01
• NCT#: NCT05478538

Study Name: Tempus Gemini

• Cancer Stage: All
• Key Inclusion: Cohort 1: Known/suspected NSCLC w/curative intent; Cohort 2: Stage IV
• Description: A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Non-Small Cell Lung Cancer (NSCLC).
• Study Number: Tempus Gemini
• NCT#: NCT05236114

Study Name: BNT327-03

• Cancer Stage: IV
• Key Inclusion: Small Cell
• Description: Safety and efficacy of BNT327, an investigational therapy in combination with chemotherapy for patients with untreated small-cell lung cancer
• Study Number: N/A
• NCT#: NCT06449209

Study Name: BNT327-06

• Cancer Stage: IV
• Key Inclusion: Adenocarcinoma
• Description: Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
• Study Number: BNT327-06
• NCT#: NCT06712316

Study Name: Artemide

• Cancer Stage: IV
• Key Inclusion: PDL1+
• Description: A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
• Study Number: D702FC00001
• NCT#: NCT06627647

For more information, call 240-566-4100